Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Anavex Comments on Failure of Pfizer and Medivation’s Dimebon

March 3, 2010

Anavex Appoints Dr. Cameron Durrant Executive Chairman of the Board

January 18, 2010

Anavex Contracts FORENAP Pharma for Pre-Clinical Trials of ANAVEX 2-73 in Alzheimer’s Disease.

September 30, 2009

Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase I Alzheimer’s Disease Clinical Trials

September 21, 2009

Anavex Reports Sigma Receptor Review Published in Leading Journal

August 27, 2009

Anti-amnesic and neuroprotective activities of ANAVEX2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligand, in pharmacological and pathological models of amnesia.

July 11, 2009

ANAVEX Appoints Dr. Hervé de Kegrohen as CEO to Lead Company Through Clinical Trials and Future Growth

June 16, 2009

Pharmawire: Medivation, Anavex May Lower Oxidative Stress

April 8, 2009

Anavex Appoints Leading Alzheimer’s Disease Expert Dr. Mark Smith to Scientific Advisory Board

February 10, 2009

Anavex Scales Up Synthesis of ANAVEX 2-73 for Phase 1 Alzheimer’s Disease Study

January 30, 2009

Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology

December 17, 2008

Anavex Presents Potent Neuroprotective Effects of ANAVEX 1-41 at Neuroscience 2008

December 4, 2008
1
234567891011121314151617181920212223242526272829
…3031323334…
3536373839404142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top